Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
出版年份 2018 全文链接
标题
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
作者
关键词
-
出版物
MOVEMENT DISORDERS
Volume 33, Issue 5, Pages 660-677
出版商
Wiley
发表日期
2018-04-12
DOI
10.1002/mds.27360
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Clinical approaches to the development of a neuroprotective therapy for PD
- (2017) C.W. Olanow et al. EXPERIMENTAL NEUROLOGY
- Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
- (2017) Andrew B. West EXPERIMENTAL NEUROLOGY
- Targeting urate to reduce oxidative stress in Parkinson disease
- (2017) Grace F. Crotty et al. EXPERIMENTAL NEUROLOGY
- Therapeutic approaches to target alpha-synuclein pathology
- (2017) Patrik Brundin et al. EXPERIMENTAL NEUROLOGY
- Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification
- (2017) Javier Blesa et al. EXPERIMENTAL NEUROLOGY
- Targeting LRRK2 in Parkinson’s disease: an update on recent developments
- (2017) Sharon L. Chan et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Potential Modes of Intercellular α-Synuclein Transmission
- (2017) Dario Valdinocci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress
- (2017) Lisa D. Coles et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subthalamic Nucleus Deep Brain Stimulation Employs trkB Signaling for Neuroprotection and Functional Restoration
- (2017) D. Luke Fischer et al. JOURNAL OF NEUROSCIENCE
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Can lifestyle changes prevent cognitive impairment?
- (2017) Miia Kivipelto et al. LANCET NEUROLOGY
- Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
- (2017) David J Irwin et al. LANCET NEUROLOGY
- Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial
- (2017) Sandrine Andrieu et al. LANCET NEUROLOGY
- New perspectives on study designs for evaluating neuroprotection in Parkinson's disease
- (2017) Laetitia Thibault et al. MOVEMENT DISORDERS
- Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database
- (2017) Guodong Liu et al. MOVEMENT DISORDERS
- Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins
- (2017) C. Warren Olanow et al. MOVEMENT DISORDERS
- Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials
- (2017) Alberto J. Espay et al. MOVEMENT DISORDERS
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
- (2017) J.A. Obeso et al. MOVEMENT DISORDERS
- α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
- (2017) Yvette C Wong et al. NATURE MEDICINE
- Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease
- (2017) Subhojit Roy NATURE NEUROSCIENCE
- Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration
- (2017) Danielle E Mor et al. NATURE NEUROSCIENCE
- Zeroing in on neurodegenerative α-synuclein
- (2017) Katie Kingwell NATURE REVIEWS DRUG DISCOVERY
- Precision medicine for disease modification in Parkinson disease
- (2017) Alberto J. Espay et al. Nature Reviews Neurology
- Long-term effects of exercise and physical therapy in people with Parkinson disease
- (2017) Margaret K. Mak et al. Nature Reviews Neurology
- Selective neuronal vulnerability in Parkinson disease
- (2017) D. James Surmeier et al. NATURE REVIEWS NEUROSCIENCE
- Caffeine as symptomatic treatment for Parkinson disease (Café-PD)
- (2017) Ronald B. Postuma et al. NEUROLOGY
- Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
- (2017) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
- (2017) Michele Perni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
- (2017) Shuchi Mittal et al. SCIENCE
- LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
- (2017) Hien Tran Zhao et al. Molecular Therapy-Nucleic Acids
- Parkinson disease
- (2017) Werner Poewe et al. Nature Reviews Disease Primers
- A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)
- (2017) Kevin M. Biglan et al. Annals of Clinical and Translational Neurology
- Statin adherence and the risk of Parkinson's disease: A population-based cohort study
- (2017) Violetta Rozani et al. PLoS One
- Statin therapy prevents the onset of Parkinson disease in patients with diabetes
- (2016) Kun-Der Lin et al. ANNALS OF NEUROLOGY
- A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
- (2016) David J. M. McGhee et al. BMC Neurology
- Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease
- (2016) Timothy R. Sampson et al. CELL
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts
- (2016) Diane M A Swallow et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial
- (2016) Eric P Moll van Charante et al. LANCET
- Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease
- (2016) Naveed Malek et al. MOVEMENT DISORDERS
- Study ofLRRK2variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration
- (2016) Monica Sanchez-Contreras et al. MOVEMENT DISORDERS
- Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
- (2016) Maria Xilouri et al. MOVEMENT DISORDERS
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson’s Disease
- (2016) Yan Xu et al. NEUROCHEMICAL RESEARCH
- Challenges in detecting disease modification in Parkinson's disease clinical trials
- (2016) Dilan Athauda et al. PARKINSONISM & RELATED DISORDERS
- Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3
- (2016) X. Mao et al. SCIENCE
- α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era
- (2016) Naomi P. Visanji et al. TRENDS IN NEUROSCIENCES
- Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
- (2016) Fernando Pagan et al. Journal of Parkinsons Disease
- Merging DBS with viral vector or stem cell implantation: “hybrid” stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease
- (2016) Nathan C Rowland et al. Molecular Therapy-Methods & Clinical Development
- Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
- (2015) C. Warren Olanow et al. ANNALS OF NEUROLOGY
- Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson’s disease: the LEAP-study
- (2015) Constant V. M. Verschuur et al. BMC Neurology
- Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
- (2015) Guillaume Grolez et al. BMC Neurology
- Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
- (2015) Aurelija Jucaite et al. BRAIN
- LRRK2 Pathways Leading to Neurodegeneration
- (2015) Mark R. Cookson Current Neurology and Neuroscience Reports
- Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system
- (2015) Katrina L. Paumier et al. EXPERIMENTAL NEUROLOGY
- Building a roadmap for developing combination therapies for Alzheimer’s disease
- (2015) Daniel Perry et al. Expert Review of Neurotherapeutics
- A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial
- (2015) Tiia Ngandu et al. LANCET
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease
- (2015) Mattia Volta et al. LANCET NEUROLOGY
- Neuropathology of α-synuclein propagation and braak hypothesis
- (2015) Heather McCann et al. MOVEMENT DISORDERS
- Trophic factors for Parkinson's disease: To live or let die
- (2015) C. Warren Olanow et al. MOVEMENT DISORDERS
- Combination therapies: The next logical Step for the treatment of synucleinopathies?
- (2015) Elvira Valera et al. MOVEMENT DISORDERS
- Development of Passive Immunotherapies for Synucleinopathies
- (2015) Ann-Louise Bergström et al. MOVEMENT DISORDERS
- Active immunization therapies for Parkinson's disease and multiple system atrophy
- (2015) Achim Schneeberger et al. MOVEMENT DISORDERS
- Disease-modifying strategies for Parkinson's disease
- (2015) Lorraine V. Kalia et al. MOVEMENT DISORDERS
- MDS research criteria for prodromal Parkinson's disease
- (2015) Daniela Berg et al. MOVEMENT DISORDERS
- Cell-based therapies for Parkinson disease—past insights and future potential
- (2015) Roger A. Barker et al. Nature Reviews Neurology
- Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration
- (2015) Katrina L. Paumier et al. NEUROBIOLOGY OF DISEASE
- The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
- (2015) Alicia M. Pickrell et al. NEURON
- Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease
- (2015) Mallory L. Hacker et al. PARKINSONISM & RELATED DISORDERS
- Building a roadmap for developing combination therapies for Alzheimer’s disease
- (2015) Daniel Perry et al. Expert Review of Neurotherapeutics
- Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease
- (2015) Lorraine V. Kalia et al. JAMA Neurology
- Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials
- (2014) Markus Mandler et al. ACTA NEUROPATHOLOGICA
- Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
- (2014) Alisdair McNeill et al. BRAIN
- Charting a path toward combination therapy for Alzheimer’s disease
- (2014) Diane Stephenson et al. Expert Review of Neurotherapeutics
- c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
- (2014) Anne-Laure Mahul-Mellier et al. HUMAN MOLECULAR GENETICS
- Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
- (2014) Stéphane Palfi et al. LANCET
- Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease
- (2014) Anke A. Dijkstra et al. MOVEMENT DISORDERS
- Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
- (2014) B. Ritz et al. NEUROLOGY
- Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study
- (2014) C. H. Adler et al. NEUROLOGY
- Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?
- (2014) M.G. Rizzone et al. PARKINSONISM & RELATED DISORDERS
- Concomitant pathologies among a spectrum of parkinsonian disorders
- (2014) Brittany N. Dugger et al. PARKINSONISM & RELATED DISORDERS
- The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
- (2014) Senthilkumar S. Karuppagounder et al. Scientific Reports
- Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
- (2013) David Devos et al. ANTIOXIDANTS & REDOX SIGNALING
- Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
- (2013) Jeffrey H. Kordower et al. BRAIN
- Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
- (2013) Amaal AlDakheel et al. Neurotherapeutics
- A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
- (2013) Michael A. Nalls et al. JAMA Neurology
- Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease
- (2013) Zinovia Kefalopoulou et al. JAMA Neurology
- Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model
- (2012) Zacharias Kohl et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy
- (2012) Kiren Ubhi et al. EXPERIMENTAL NEUROLOGY
- Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
- (2012) Gabriele Mittermeyer et al. HUMAN GENE THERAPY
- Parkinson's disease subtypes: lost in translation?
- (2012) C. Marras et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease
- (2012) Katrina L. Paumier et al. MOVEMENT DISORDERS
- Trial designs used to study neuroprotective therapy in Parkinson's disease
- (2012) Anthony E. Lang et al. MOVEMENT DISORDERS
- Living on the edge with too many mouths to feed: Why dopamine neurons die
- (2012) J. Paul Bolam et al. MOVEMENT DISORDERS
- Deep brain stimulation in early stage Parkinson's disease: operative experience from a prospective randomised clinical trial
- (2011) Elyne Kahn et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Glia: Initiators and progressors of pathology in Parkinson's disease
- (2011) Glenda M. Halliday et al. MOVEMENT DISORDERS
- Use of ibuprofen and risk of Parkinson disease
- (2011) X. Gao et al. NEUROLOGY
- Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment
- (2010) Andrew Siderowf et al. ANNALS OF NEUROLOGY
- Dopaminergic transplantation for parkinson's disease: Current status and future prospects
- (2009) C. Warren Olanow et al. ANNALS OF NEUROLOGY
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
- (2009) E. Sidransky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
- (2008) Mariese A. Hely et al. MOVEMENT DISORDERS
- Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation
- (2008) Jia-Yi Li et al. NATURE MEDICINE
- Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
- (2008) Jeffrey H Kordower et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search